(Q38078264)

28 August 2017

1 reference

title

Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics (English)

1 reference

28 August 2017

Evan A Stein

1

1 reference

PubMed ID

23371064

28 August 2017

Gary D Swergold

series ordinal

2

1 reference

28 August 2017

1 March 2013

1 reference

Current Atherosclerosis Reports

28 August 2017

1 reference

28 August 2017

15

1 reference

28 August 2017

3

1 reference

28 August 2017

310

1 reference

https://scigraph.springernature.com/pub.10.1007/s11883-013-0310-3

28 August 2017

0 references

cites work

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0310-3

Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0310-3

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0310-3

Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0310-3

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0310-3

Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0310-3

The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0310-3

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0310-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0310-3

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0310-3

Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0310-3

Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0310-3

Recent patents on PCSK9: a new target for treating hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0310-3

NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0310-3

Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0310-3

Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0310-3

Molecular basis for LDL receptor recognition by PCSK9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0310-3

Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0310-3

Interaction between the ligand-binding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0310-3

Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0310-3

In vivo evidence that furin from hepatocytes inactivates PCSK9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0310-3

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0310-3

Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0310-3

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised con

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0310-3

Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 In

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0310-3

Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0310-3

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0310-3

Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0310-3

The Friedewald formula underestimates LDL cholesterol at low concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0310-3

Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0310-3

Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0310-3

A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0310-3

Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

21 January 2018

1 reference

12 December 2020

Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy

1 reference

12 December 2020

Familial hypercholesterolaemia: the Cape Town experience.

1 reference

12 December 2020

Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways

1 reference

12 December 2020

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

1 reference

12 December 2020

The rule of 5 and the rule of 7 in lipid-lowering by statin drugs.

1 reference

12 December 2020

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study

1 reference

12 December 2020

Role of ubiquitination in PCSK9-mediated low-density lipoprotein receptor degradation

1 reference

12 December 2020

Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia

1 reference

12 December 2020

10.1007/S11883-013-0310-3

Identifiers

DOI

1 reference

PubMed ID

23371064

Dimensions Publication ID

28 August 2017

0 references

1 reference

PubMed ID

23371064